Stock listing
Frankfurt:IMR AC Immune SA Aktie
German listing (Frankfurt) of AC Immune SA · home listing NASDAQ:ACIU
Follow AC Immune SA into a list and get an email when it puts out news.
Share price · FWB:IMR
€1.82 EUR +0.04 (+2.2%)
Close on Nov 20, 2026
- Day range
- €1.82 – €1.86 EURNov 20, 2026
- Market cap
- €181.0M EURAt the close on Nov 20, 2026 · price × 99.43M shares outstanding
- 52-week range
- €1.76 – €3.24 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €6,264 EURMedian day 0 shares · 31 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACIU · Home | $1.95 USD | -0.15 (-7.1%) | 298,383 | $2.16 | $2.16 | $1.93 | $2.10 | Close on Nov 20, 2026 |
| Frankfurt:IMR | €1.82 EUR | +0.04 (+2.2%) | — | €1.856 | €1.856 | €1.82 | €1.78 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:IMR · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.94 | +0.096 | +5.2% | €1.79 | €1.961 | €1.787 | 0 | |
| €1.844 | -0.109 | -5.6% | €1.942 | €1.942 | €1.783 | 6,572 | |
| €1.953 | +0.117 | +6.4% | €1.813 | €1.963 | €1.801 | 6,572 | |
| €1.836 | +0.009 | +0.5% | €1.799 | €1.843 | €1.784 | 0 | |
| €1.827 | -0.205 | -10.1% | €1.901 | €1.928 | €1.826 | 0 | |
| €2.032 | -0.017 | -0.8% | €2.032 | €2.032 | €2.032 | 3,400 | |
| €2.049 | +0.128 | +6.7% | €2.031 | €2.056 | €1.989 | 7,048 | |
| €1.921 | -0.022 | -1.1% | €1.921 | €1.921 | €1.921 | 20,812 | |
| €1.943 | -0.114 | -5.5% | €2.00 | €2.013 | €1.942 | 0 | |
| €2.057 | -0.085 | -4.0% | €2.059 | €2.082 | €2.04 | 20,074 | |
| €2.142 | +0.065 | +3.1% | €2.142 | €2.142 | €2.142 | 1,400 | |
| €2.077 | -0.095 | -4.4% | €2.077 | €2.077 | €2.077 | 0 | |
| €2.172 | -0.01 | -0.5% | €2.144 | €2.173 | €2.14 | 0 | |
| €2.182 | +0.082 | +3.9% | €2.109 | €2.188 | €2.106 | 0 | |
| €2.10 | -0.024 | -1.1% | €2.06 | €2.11 | €2.055 | 0 | |
| €2.124 | +0.018 | +0.9% | €2.124 | €2.124 | €2.124 | 0 | |
| €2.106 | +0.036 | +1.7% | €2.05 | €2.113 | €2.048 | 0 | |
| €2.07 | -0.086 | -4.0% | €2.07 | €2.07 | €2.07 | 0 | |
| €2.156 | -0.001 | 0.0% | €2.15 | €2.169 | €2.116 | 0 | |
| €2.157 | -0.024 | -1.1% | €2.157 | €2.157 | €2.157 | 0 | |
| €2.181 | -0.03 | -1.4% | €2.181 | €2.181 | €2.181 | 1,700 | |
| €2.211 | -0.024 | -1.1% | €2.211 | €2.211 | €2.211 | 830 | |
| €2.235 | +0.026 | +1.2% | €2.18 | €2.246 | €2.179 | 0 | |
| €2.209 | -0.126 | -5.4% | €2.35 | €2.35 | €2.208 | 0 | |
| €2.335 | -0.039 | -1.6% | €2.335 | €2.335 | €2.335 | 0 | |
| €2.374 | -0.068 | -2.8% | €2.375 | €2.375 | €2.373 | 20,000 | |
| €2.442 | +0.24 | +10.9% | €2.265 | €2.472 | €2.252 | 0 | |
| €2.202 | -0.019 | -0.9% | €2.203 | €2.203 | €2.201 | 1,000 | |
| €2.221 | +0.083 | +3.9% | €2.221 | €2.221 | €2.221 | 0 | |
| €2.138 | +0.013 | +0.6% | €2.138 | €2.138 | €2.138 | 0 | |
| €2.125 | -0.201 | -8.6% | €2.251 | €2.251 | €2.102 | 25,096 | |
| €2.326 | -0.096 | -4.0% | €2.373 | €2.392 | €2.319 | 0 | |
| €2.422 | +0.103 | +4.4% | €2.291 | €2.423 | €2.281 | 9,495 | |
| €2.319 | +0.088 | +3.9% | €2.208 | €2.358 | €2.207 | 0 | |
| €2.231 | -0.029 | -1.3% | €2.228 | €2.264 | €2.222 | 2,561 | |
| €2.26 | +0.031 | +1.4% | €2.27 | €2.272 | €2.25 | 2,800 | |
| €2.229 | -0.149 | -6.3% | €2.229 | €2.229 | €2.229 | 0 | |
| €2.378 | +0.135 | +6.0% | €2.265 | €2.38 | €2.253 | 1,000 | |
| €2.243 | -0.056 | -2.4% | €2.237 | €2.268 | €2.228 | 0 | |
| €2.299 | +0.065 | +2.9% | €2.313 | €2.313 | €2.278 | 0 | |
| €2.234 | -0.059 | -2.6% | €2.234 | €2.234 | €2.234 | 1,522 | |
| €2.293 | -0.086 | -3.6% | €2.293 | €2.293 | €2.293 | 0 | |
| €2.379 | +0.029 | +1.2% | €2.327 | €2.38 | €2.292 | 100 | |
| €2.35 | -0.01 | -0.4% | €2.362 | €2.362 | €2.35 | 0 | |
| €2.36 | -0.08 | -3.3% | €2.36 | €2.36 | €2.36 | 760 | |
| €2.44 | +0.072 | +3.0% | €2.44 | €2.44 | €2.44 | 4,810 | |
| €2.368 | +0.152 | +6.9% | €2.368 | €2.368 | €2.368 | 0 | |
| €2.216 | +0.015 | +0.7% | €2.216 | €2.216 | €2.216 | 1,400 | |
| €2.201 | -0.001 | 0.0% | €2.201 | €2.201 | €2.201 | 0 | |
| €2.202 | -0.039 | -1.7% | €2.202 | €2.202 | €2.202 | 1,454 | |
| €2.241 | -0.097 | -4.1% | €2.241 | €2.241 | €2.241 | 20,000 | |
| €2.338 | -0.09 | -3.7% | €2.344 | €2.345 | €2.319 | 4,600 | |
| €2.428 | +0.098 | +4.2% | €2.428 | €2.428 | €2.428 | 0 | |
| €2.33 | -0.056 | -2.3% | €2.33 | €2.33 | €2.33 | 0 | |
| €2.386 | +0.083 | +3.6% | €2.386 | €2.386 | €2.386 | 200 | |
| €2.303 | +0.163 | +7.6% | €2.188 | €2.311 | €2.171 | 430 | |
| €2.14 | +0.006 | +0.3% | €2.14 | €2.14 | €2.14 | 0 |
- Ticker
- Frankfurt:IMR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 11, 2026
AC Immune to Present at Jefferies Global Healthcare Conference 2026
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 18 slides
Latest news
AC Immune Third Quarter 2026 Financial and Corporate Update
Nov 4, 2026
Closed €1.95 (+6.4%) on Nov 4, 2026
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
Aug 11, 2026
Closed €1.88 (-3.9%) on Aug 11, 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
Jul 7, 2026
Closed €2.12 (+2.4%) on Jul 7, 2026
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
Jun 30, 2026
Closed €2.07 (-2.7%) on Jun 30, 2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
Jun 11, 2026
Closed €1.76 (-7.6%) on Jun 11, 2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 22, 2026
Closed €2.38 (-0.6%) on May 22, 2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
May 12, 2026
Closed €2.34 (-2.5%) on May 12, 2026
AC Immune First Quarter 2026 Financial and Corporate Updates
Apr 30, 2026
Closed €2.49 (-0.8%) on Apr 30, 2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Apr 30, 2026
Closed €2.49 (-0.8%) on Apr 30, 2026
AC Immune SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 124 in all · newest Nov 11, 2026 · oldest 2019
- Decks
- 27 decks · latest October 2026
Where AC Immune SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACIU · Home listing | NASDAQ | United States | USD |
| gettex:IMR | gettex | Germany | EUR |
| LS Exchange:A2AR5F | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AR5F | Lang & Schwarz | Germany | EUR |
| Frankfurt:IMR · This page | Frankfurt | Germany | EUR |
| BOATS:ACIU | BOATS | United States | USD |
| Tradegate:IMR | Tradegate | Germany | EUR |
| Dusseldorf:IMR | Dusseldorf | Germany | EUR |
| Hamburg:IMR | Hamburg | Germany | EUR |
| Munich:IMR | Munich | Germany | EUR |
| Stuttgart:IMR | Stuttgart | Germany | EUR |
| Hanover:IMR | Hanover | Germany | EUR |
| Xetra:IMR | Xetra | Germany | EUR |
Valuation
EV/sales 4.7× against a median of 14.0×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $110.5M USD
- P/E
- Loss
- EV/sales
- 4.7×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.0×
- Gross margin
- 100.0%
- Operating margin
- −190.8%
- Net margin
- −181.9%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| Cabaletta Bio, Inc. · NASDAQ:CABA | US$201.9M | −US$97.45M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.89 |
| Bright Minds Biosciences Inc. · CSE:DRUG | US$199.5M | −US$15.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.32 |
| Newron Pharmaceuticals S.p.A. · SIX:NWRN | US$199.5M | US$206.2M | n/a | 9.8× | n/a | n/a | −69.2% | n/a | n/a |
| NervGen Pharma Corp. · NASDAQ:NGEN | US$198.4M | US$137.8M | n/a | n/a | n/a | 16.4× | n/a | 0.0× | 1.46 |
| BioAge Labs, Inc. · NASDAQ:BIOA | US$196.4M | −US$87.20M | n/a | −10.1× | n/a | 0.6× | n/a | 0.0× | 2.06 |
| Lineage Cell Therapeutics, Inc. · AMEX:LCTX | US$195.3M | US$152.1M | 111× | 14.0× | n/a | 2.9× | 16.2% | 0.0× | 1.33 |
| AN2 Therapeutics, Inc. · NASDAQ:ANTX | US$192.8M | US$128.4M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.54 |
| SillaJen, Inc. · KRX:215600 | US$192.3M | US$140.8M | n/a | 17.6× | n/a | 2.6× | −223.8% | 0.0× | n/a |
| Cartesian Therapeutics, Inc. · NASDAQ:RNAC | US$187.3M | US$114.5M | n/a | 112× | n/a | n/a | n/a | n/a | 1.23 |
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| Median of the others | US$195.8M | US$121.4M | 111× | 14.0× | 1.7× | −69.2% | 0.0× | 1.34 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.34 · 2 analysts
- Revenue, year to Dec 2026
- 22M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gary Waanders | SVP, Investor Relations & Corporate Communications |
Board
| Director | Role |
|---|---|
| Monika Bütler | Chairperson |
| Renée Aguiar-Lucander | Member |
| Roy Twyman | Member |
| Thomas Graney | Member |
Events
- Next results
- Mar 11, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +9.6% |
| Q2 2026 | Aug 5, 2026 · Before open | +0.9% |
| Q1 2026 | Apr 30, 2026 · Before open | +3.4% |
| Q4 2025 | Mar 12, 2026 | −1.5% |
| Q3 2025 | Nov 4, 2025 · Before open | +3.8% |
| Q2 2025 | Aug 5, 2025 · Before open | +11.6% |
| Q1 2025 | Apr 30, 2025 · Before open | +1.8% |
| Q4 2024 | Mar 12, 2025 · Before open | +3.1% |
| Q3 2024 | Nov 5, 2024 · Before open | +10.2% |
| Q2 2024 | Aug 6, 2024 · Before open | +1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +42.9% |
| Q4 2023 | Mar 14, 2024 · Before open | −10.0% |
| Q3 2023 | Nov 3, 2023 · Before open | −3.9% |
| Q2 2023 | Aug 4, 2023 · Before open | +3.1% |
| Q1 2023 | Apr 28, 2023 · Before open | +3.2% |
| Q4 2022 | Mar 16, 2023 · Before open | +0.4% |
| Q3 2022 | Oct 28, 2022 · Before open | −6.6% |
| Q2 2022 | Jul 28, 2022 · Before open | +4.4% |
| Q1 2022 | Apr 28, 2022 · Before open | −0.9% |
| Q4 2021 | Mar 22, 2022 · Before open | −0.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 18 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Shareholder Meeting (June 2026) | Shareholder meeting | 43 slides | Jun 11, 2026 |
| Shareholder Meeting (June 2025) | Shareholder meeting | 47 slides | Jun 20, 2025 |
| Shareholder Meeting (June 2024) | Shareholder meeting | 39 slides | Jun 20, 2024 |
| Investor Presentation (May 2024) | Investor deck | 11 slides | May 2024 |
| AD/PD 2024 | Conference | 12 slides | Mar 9, 2024 |
| AD/PD 2024 | Conference | 13 slides | Mar 6, 2024 |
| ADPD 2024 | Conference | 11 slides | March 2024 |
| AAIC 2023 | Conference | 16 slides | Jul 18, 2023 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (June 2023) | Shareholder meeting | 49 slides | Jun 26, 2023 |
| AAIC 2022 | Conference | 13 slides | Aug 2, 2022 |
| Shareholder Meeting (June 2022) | Shareholder meeting | 50 slides | Jun 24, 2022 |
| AD/PD 2022 | Conference | 12 slides | Mar 18, 2022 |
| CTAD 2021 (Clinical Trials on Alzheimer's Disease), Boston | Conference | 15 slides | November 2021 |
| Shareholder Meeting (June 2021) | Shareholder meeting | 37 slides | Jun 25, 2021 |
| Shareholder Meeting (June 2020) | Shareholder meeting | 34 slides | Jun 26, 2020 |
| Investor Presentation (November 2019) | Investor deck | 26 slides | Nov 6, 2019 |
| Technical Presentation (November 2019) | Technical | 32 slides | Nov 6, 2019 |
| KOL Breakfast NYC July 2019 | Conference | 25 slides | Jul 11, 2019 |
| Shareholder Meeting (June 2019) | Shareholder meeting | 53 slides | Jun 28, 2019 |
| CTAD 2018 late breaking session | Conference | 18 slides | Oct 26, 2018 |
| Shareholder Meeting (July 2018) | Shareholder meeting | 53 slides | Jul 6, 2018 |
| Shareholder Meeting (April 2018) | Shareholder meeting | 26 slides | Apr 27, 2018 |
| Shareholder Meeting (June 2017) | Shareholder meeting | 47 slides | Jun 28, 2017 |
| Technical Presentation (December 2016) | Technical | 10 slides | Dec 16, 2016 |
| Shareholder Meeting (November 2016) | Shareholder meeting | 16 slides | Nov 15, 2016 |
IPO
Priced at US$11.00 a share on Sep 22, 2016.
- Price
- US$11.00 a share
- Shares offered
- 6,000,000 common shares
- Offering size
- US$66 million
- Underwriters' option
- Up to 900,000 more shares
- Underwriters
- Credit Suisse, Jefferies, Leerink Partners · In the order on the cover
- Shares delivered
- On or about Sep 28, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 28, 2015 |
| Filed publicly | May 31, 2016 |
| Amended 7 times | Newest Sep 22, 2016 |
| Declared effective by the SEC | Sep 22, 2016 |
| Shares registered with an exchange | Sep 23, 2016 |
| Final prospectus, with the price | Sep 23, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 23, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Sep 23, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 23, 2016 |
| EFFECT · Notice that a registration is effective | Sep 22, 2016 |
| F-1/A · Registration statement, amended | Sep 22, 2016 |
| FWP · Free writing prospectus | Sep 21, 2016 |
| F-1/A · Registration statement, amended | Sep 21, 2016 |
| CORRESP · Letter to the SEC | Sep 20, 2016 |
| CORRESP · Letter to the SEC | Sep 20, 2016 |
| CORRESP · Letter to the SEC | Sep 20, 2016 |
All 40 filings
Open IPO · From the cover of the final prospectus (424B4) filed Sep 23, 2016
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.57M | 27.3M | 14.8M | 3.94M | 0 | 15.4M | 110.5M | 6.91M | 20.3M | 23.2M |
| Cost of revenue | 62.6M | 54.6M | 60.3M | 62.3M | 59.5M | 50.4M | 44.3M | 32.7M | 25.8M | |
| Gross profit | 3.57M | -35.3M | -39.8M | 3.94M | -62.3M | -44.1M | 60.0M | -37.1M | -12.4M | -2.56M |
| Research and development | 56.4M | 62.6M | 54.6M | 60.3M | 62.3M | 59.5M | 50.4M | 44.3M | 32.7M | 25.8M |
| Selling, general and administrative | 11.7M | 11.4M | 10.6M | 9.58M | 17.9M | 18.6M | 16.1M | 12.5M | 10.1M | 7.90M |
| Operating income | -69.3M | -52.4M | -53.6M | -70.8M | -79.0M | -61.3M | 44.5M | -49.5M | -22.5M | -10.5M |
| Depreciation and amortization | 1.39M | 1.49M | 1.67M | 1.79M | 1.90M | 1.53M | 1.27M | 961.0K | 580.0K | 278.0K |
| EBITDA | -67.9M | -50.9M | -52.0M | -69.1M | -77.1M | -59.7M | 45.8M | -48.6M | -22.0M | -10.2M |
| Interest expense | 191.0K | 133.0K | 176.0K | 355.0K | 581.0K | 184.0K | 1.89M | 298.0K | 147.0K | 7.00K |
| Income before tax | -70.4M | -50.9M | -54.2M | -70.7M | -73.0M | -61.9M | 45.4M | -51.0M | -26.4M | -7.10M |
| Income tax | 0 | 3.00K | 10.0K | 13.0K | 3.00K | 0 | 0 | 0 | 0 | 0 |
| Net income | -70.4M | -50.9M | -54.2M | -70.8M | -73.0M | -61.9M | 45.4M | -51.0M | -26.4M | -7.10M |
| Earnings per share, basic | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 | -0.86 | 0.64 | -0.82 | -0.46 | -0.14 |
| Earnings per share, diluted | -0.70 | -0.51 | -0.64 | -0.85 | -0.97 | -0.86 | 0.64 | -0.82 | -0.46 | -0.14 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.8M | 36.3M | 78.5M | 31.6M | 82.2M | 160.9M | 193.6M | 156.5M | 124.4M | 152.2M |
| Short-term investments | 64.7M | 129.2M | 24.6M | 91.0M | 116.0M | 65.0M | 95.0M | 30.0M | 0 | 0 |
| Receivables | 1.34M | 0 | 14.8M | 408.0K | 975.0K | 1.59M | 1.40M | 4.10M | 3.72M | 1.41M |
| Inventory | -622.0K | 1 | -1.40M | -1.92M | -1.40M | 0 | -1.36M | 389.0K | ||
| Current assets | 96.7M | 172.0M | 125.2M | 128.1M | 202.6M | 231.8M | 292.8M | 192.9M | 129.5M | 154.9M |
| Property, plant and equipment | 1.99M | 2.65M | 3.38M | 4.26M | 5.12M | 4.42M | 3.92M | 3.32M | 2.35M | 1.12M |
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 154.3M | 230.9M | 182.8M | 185.9M | 261.4M | 238.7M | 299.3M | 196.6M | 132.0M | 156.1M |
| Accounts payable | 2.07M | 2.66M | 1.68M | 929.0K | 2.00M | 2.18M | 142.0K | 1.98M | 1.09M | 4.04M |
| Current liabilities | 94.7M | 100.8M | 13.6M | 11.5M | 20.0M | 14.0M | 17.5M | 13.1M | 9.75M | 9.92M |
| Long-term debt | 0 | 186.0K | 395.0K | 0 | ||||||
| Total debt | 4.55M | 5.43M | 3.50M | 2.80M | 2.91M | 2.22M | 2.91M | 551.8K | 498.4K | 0 |
| Total liabilities | 109.4M | 118.6M | 22.2M | 16.9M | 29.5M | 23.3M | 26.8M | 18.9M | 15.2M | 13.7M |
| Shareholders' equity | 44.9M | 112.3M | 160.6M | 169.0M | 232.0M | 215.5M | 272.4M | 177.6M | 116.8M | 142.4M |
| Shares outstanding | 100.8M | 99.7M | 84.7M | 83.6M | 75.0M | 71.9M | 71.1M | 61.8M | 57.4M | 50.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -69.3M | 65.8M | -60.4M | -73.6M | -65.7M | -59.5M | 55.2M | -44.1M | -22.1M | -5.65M |
| Capital spending | -900.0K | -576.0K | -801.0K | -1.24M | -2.63M | -1.71M | -1.89M | -1.86M | -1.80M | -899.0K |
| Free cash flow | -70.2M | 65.3M | -61.2M | -74.8M | -68.3M | -61.2M | 53.3M | -45.9M | -23.9M | -6.54M |
| Cash from investing | 63.5M | -105.3M | 65.6M | 23.8M | -53.7M | 28.3M | -66.9M | -32.0M | -1.84M | -899.0K |
| Cash from financing | -1.02M | -1.12M | 43.3M | -1.35M | 40.7M | -803.0K | 49.6M | 109.4M | 271.0K | 78.8M |
| Dividends paid | -7.00K | 0 | 0 | 0 | 0 | |||||
| Share buybacks | 0 | 0 | -100.0K | 0 | 0 | 71.0K | 82.9M | |||
| Change in cash | -6.74M | -40.6M | 48.5M | -51.2M | -78.6M | -32.0M | 38.0M | 33.3M | -23.7M | 72.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 4, 2026 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Oct 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 9, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Oct 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 23, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 11, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 313 filings. Open Filings
Cap table
Built by 6ix from AC Immune SA’s releases
- Common shares
- 99,426,932
- Fully diluted
- 99,426,932
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 99,426,932 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 99,426,932 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Renée Aguiar-Lucander Other companies: Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past) | Member · Since at least Mar 18, 2026 |
| Andrea Pfeifer | Chief Executive Officer, Director · Since at least Mar 18, 2026 |
| Carl Howard June | Director · Since at least Mar 18, 2026 |
| Christopher James Roberts | Chief Financial Officer · Since at least Mar 18, 2026 |
| Gary Waanders | SVP, Investor Relations & Corporate Communications · Since at least Nov 4, 2026 |
| Martin Zuegel | Interim CEO, Director · Since at least Mar 18, 2026 |
| Monika Buetler | Director · Since at least Mar 18, 2026 |
| Monika Bütler | Chairperson · Since at least Nov 5, 2026 |
| Piergiorgio Donati | Chief Operating Officer · Since at least Mar 20, 2026 |
| Roy Twyman | Member · Since at least Mar 18, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Thomas Graney | Member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about AC Immune SA.